Background: Vascular calcification (VC) is a severe vascular complication of metabolic syndrome (MetS), strongly correlated with increased cardiovascular morbidity and mortality. One of the most important regulator of osteoblastic differentiation, runt-related transcription factor-2 (RUNX2) has a crucial role in VC by promoting the transformation of vascular smooth muscle cells (VSMCs) toward an osteoblast-like phenotype.Objective: This study explored the effect of MetS on VC by raising RUNX2 mRNA expression and how metformin and empagliflozin affect RUNX2 mRNA expression in MetS-induced rats.Methods: Twenty Sprague-Dawley male rats were randomly separated into four groups: negative control (NC), MetS, MetS treated with metformin 500 mg/kgBW/day, and MetS treated with empagliflozin 30 mg/kgBW/day. MetS was induced by a high-fat high-sucrose diet and low-dose streptozotocin injection. RUNX2 mRNA expression was measured using RT-PCR and aortic tissue was stained using hematoxylin-eosin.Result: MetS induction resulted in visible microcalcification within the aortic wall and significantly increased RUNX2 mRNA expression compared with the NC group (mean ± SD: 38 ± 15, p = 0.01), indicating enhanced VC. Metformin markedly reduced RUNX2 mRNA expression (mean ± SD: 73 ± 7, p = 0.03), whereas empagliflozin showed a non-significant decrease (mean ± SD: 76 ± 23, p = 0.87). Conclusion: MetS induction can stimulate VC accompanied by increased RUNX2 mRNA expression in rats aortic tissue. Metformin and empagliflozin mitigate these changes, with metformin showing a more pronounced effect. This strengthens the importance of controlling MetS to reduce the risk of VC.
Copyrights © 2026